Earendil Labs raised $787 million in a financing round to accelerate an AI‑driven biologics pipeline spanning autoimmune and oncology indications. The round included strategic investors and pharma partners, the company said, and will bankroll multiple preclinical and clinical programs as well as R&D expansion in both the U.S. and China. Earendil reported more than 40 programs in discovery and said at least one program for inflammatory bowel disease is ready for Phase 2. The company emphasized its platform throughput and cited prior partnership agreements with major pharma as validation for its AI‑enabled discovery model. Investors view the round as evidence that deep capital can scale AI‑first biotech R&D from discovery into clinical development, intensifying competition for talent and deal flow between U.S.‑ and China‑rooted players.